Validation of the TheraMe! Approach in a mouse xenograft model (mice growing human pancreatic tumors): Mice were treated with a drug combination that had shown most efficient killing of cancer cells in the microfluidic system (MK2206 + PHT427; purple bars). The size of the tumors (Y-axis) was monitored over time (X-axis) in comparison to mice treated with vehicle (blue bars), the clinical standard care drug against pancreatic cancer (green bars) or a negative control drug combination (yellow bars). At the end of the trial period, the tumors had massively grown in all groups, except for the mice treated according to the TheraMe! approach.